ArticlePloS one2026
An interpretable Hallmark pathway activity classifier for distinguishing CIN3/HSIL from invasive cervical squamous carcinoma: Development, external validation, and feature stability assessment.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPublic transcriptomic cohorts rarely include paired biopsy, conization, and final surgical pathology labels, making direct modeling of post-conization pathological upgrading infeasible in most public datasets. We therefore examined whether pathway-level transcriptomic activity can distinguish CIN3/HSIL from invasive cervical squamous carcinoma.
methodsGSE63514 was used for model development and GSE7803 as the primary external validation cohort. Expression matrices were mapped to gene symbols and summarized as MSigDB Hallmark pathway activity scores using ssGSEA. An elastic net logistic regression classifier was trained in GSE63514 and applied to GSE7803 without refitting or threshold re-optimization. Bootstrap resampling was used to assess feature-selection stability.
resultsThe final model retained eight Hallmark pathways. In GSE63514, the classifier achieved an AUC of 0.890 (95% CI, 0.810-0.971). In GSE7803, the locked model achieved an AUC of 0.815 (95% CI, 0.665-0.966). Bootstrap analysis showed recurrent selection of the major contributing pathways, including estrogen response early, KRAS signaling DN, TGF-beta signaling, estrogen response late, and epithelial-mesenchymal transition.
conclusionsThis study provides an interpretable pathway-level transcriptomic classifier that separates preinvasive high-grade cervical disease from invasive squamous carcinoma in public cohorts. The model should be interpreted as a molecular characterization framework rather than a clinically deployable diagnostic assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.